AstraZeneca Pharma shares rally 13%, hit 52-week high after receiving nod for cancer drug Durvalumab
The stock is trading above its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages (SMAs).
AstraZeneca Pharma gets nod to sell immunotherapy drug Durvalumab; stock surges
This surge came after the company announced approval to import and distribute Durvalumab (Imfinzi) infusion in two dosages.
AstraZeneca Pharma gets approval to launch cancer drug in India
This is to inform you that AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India, to import and distribute Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion (Imfinzi), according to a stock exchange filing.
AstraZeneca Pharma gets nod to launch cancer drug durvalumab in India
The approved indication involves using durvalumab in combination with chemotherapy as a neoadjuvant treatment, followed by durvalumab monotherapy post-surgery. Shares of Astrazeneca Pharma India Ltd ended at ₹6,
AstraZeneca Pharma receives nod for cancer drug Durvalumab; stock soars 12%
The uptick in AstraZeneca share price came after the company announced that it has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL sol from CDSO.
Cure Today7h
Imfinzi Improves Survival Outcomes in Subgroups of Patients with LS-SCLC
Among patients with limited-stage small cell lung cancer, the benefits of consolidation Imfinzi were seen across a number of ...
FiercePharma9d
ESMO: AstraZeneca's Imfinzi extends life in bladder cancer type. Will FDA push back on its perioperative trial design?
AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...
GlobalData on MSN7d
AstraZeneca’s Imfinzi and Imjudo found to extend survival in liver cancer trial
Imfinzi is a human monoclonal antibody that targets the PD-L1 protein, whereas Imjudo focuses on the CTLA-4 protein.
STAT8d
AstraZeneca’s Imfinzi increases survival rates in bladder cancer in pivotal study
If the trial design doesn't cause regulatory issues, the results could reshape how muscle-invasive bladder tumors are treated ...
Astra’s Blockbuster Drug Scores Major Win in Bladder Cancer
AstraZeneca Plc’s Imfinzi extended the lives of patients with bladder cancer, potentially opening up a new market for the ...
Cure Today11d
Imfinzi After Primary Treatment Does Not Improve Disease-Free Survival in PD-L1-Positive NSCLC
Patients with NSCLC did not see a disease-free survival benefit with Imfinzi after surgery compared with taking a placebo.
AIM Reports Positive Preliminary Data From Phase 1b/2 Study Of Ampligen, Imfinzi As Combination
AIM ImmunoTech (AIM) reported positive preliminary data from the Phase 1b/2 study evaluating the combination of Ampligen and ...